Keros Therapeutics (KROS) Net Equity Issued and Repurchased (2020 - 2024)

Keros Therapeutics' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $72.9 million for Q4 2024.

• Quarterly Net Equity Issued and Repurchased rose 6.4% year-over-year to $72.9 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $72.9 million (down 67.48% YoY) and the FY2024 annual result came in at $228.6 million, up 30.02% from the prior year.
• Net Equity Issued and Repurchased was $72.9 million for Q4 2024 at Keros Therapeutics, up from $4.4 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $151.3 million in Q1 2024 and bottomed at -$58.2 million in Q4 2022.
• A 5-year average of $48.9 million and a median of $52.2 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased tumbled 306.51% — and 2023, when it jumped 217.77%.
• Keros Therapeutics' Net Equity Issued and Repurchased stood at $56.0 million in 2020, then tumbled by 49.69% to $28.2 million in 2021, then tumbled by 306.51% to -$58.2 million in 2022, then soared by 217.77% to $68.5 million in 2023, then grew by 6.4% to $72.9 million in 2024.
• Business Quant data shows KROS's Net Equity Issued and Repurchased at $72.9 million in Q4 2024, $4.4 million in Q3 2024, and $151.3 million in Q1 2024.